Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepat

[Guest guest]

Journal of Gastroenterology and Hepatology 23 (3) , 474–481

doi:10.1111/j.1440-1746.2008.05321.x

Abstract

HEPATOLOGY

Virological and clinical implication of core promoter C1752/V1753 and

T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia

Abeer Elkady,**Department of Clinical Molecular Informative Medicine, Nagoya

City University Graduate School of Medical Sciences, Nagoya, Japan; and Yasuhito

Tanaka,**Department of Clinical Molecular Informative Medicine, Nagoya City

University Graduate School of Medical Sciences, Nagoya, Japan; and Fuat

Kurbanov,**Department of Clinical Molecular Informative Medicine, Nagoya City

University Graduate School of Medical Sciences, Nagoya, Japan; and Tsendsuren

Oynsuren††Laboratory of Molecular Biology, The Institute of Biology,

Mongolian Academy of Sciences, Ulaanbaatar, Mongolia and Masashi

Mizokami**Department of Clinical Molecular Informative Medicine, Nagoya City

University Graduate School of Medical Sciences, Nagoya, Japan; and Professor

Masashi Mizokami, Department of Clinical Molecular Informative Medicine, Nagoya

City University Graduate School of Medical Sciences, Kawasumi 1, Mizhuo, Nagoya

467-8601, Japan. Email: mizokami@... *Department of Clinical

Molecular Informative Medicine, Nagoya City University Graduate School of

Medical Sciences, Nagoya, Japan; and †Laboratory of Molecular Biology, The

Institute of Biology, Mongolian Academy of Sciences, Ulaanbaatar, Mongolia

Professor Masashi Mizokami, Department of Clinical Molecular Informative

Medicine, Nagoya City University Graduate School of Medical Sciences, Kawasumi

1, Mizhuo, Nagoya 467-8601, Japan. Email: mizokami@...

See J. Gastroenterol. Hepatol. 2008; 23: 347–350 for Editorial Comment on this

article.

Abstract

Background and Aim: The aim of the present study was to reveal virological and

clinical features of hepatitis B virus (HBV) genotype D infection.

Methods: One hundred and twenty-two Mongolian chronic liver disease (CLD)

patients infected with HBV were subjected for serological HBV-markers screening

and HBV-enzyme immunoassay (EIA) genotyping. Nucleotide sequences were analyzed

for 48 HBV/D strains (23 isolated from hepatocellular carcinoma (HCC) and 25

from CLD patients).

Results: Prevalence of hepatitis B e antigen (HBeAg) positivity was low (25.9%)

in young patients (≤30 years old) indicating early HBeAg seroclearance in

HBV/D carriers. The T1764/G1766 double mutation was the most common basal core

promoter (BCP) mutation (29.2%) and was frequent in HBeAg-negative patients

(39.3%). Patients harboring T1764/G1766 mutants exhibited lower HBV-DNA and HBV

core antigen (HBcAg) levels than those with wild-type BCP strains (P = 0.024,

0.049, respectively). C1752 and/or V (not T) 1753 mutation was significantly

prevalent in HCC patients (HCC vs CLD; 52.2% vs 20%, P = 0.033). T1762/A1764

mutation was detected in 75.0% of HCC patients with high viral load (≥5 log

copies/mL). Precore stop codon mutation A1896 was detected in (70.8%) of

HBV/D-infected patients.

Conclusions: In Mongolians infected with HBV/D, C1752 and/or V1753 mutation was

associated with HCC.

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1746.2008.05321.x

_________________________________________________________________

Helping your favorite cause is as easy as instant messaging. You IM, we give.

http://im.live.com/Messenger/IM/Home/?source=text_hotmail_join